A review of the natriuretic hormone system's diagnostic and therapeutic potential in critically ill children

Pediatric Critical Care Medicine

Volumn 7, Issue 4, 2006, Pages 308-318

  Costello, John M ^a   Goodman, Denise M ^b   Green, Thomas P ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Atrial natriuretic factor; Brain; Cardiopulmonary bypass; Congenital; Congestive; Diuretics; Heart defects; Heart failure; Natriuretic peptide

Indexed keywords

ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR ALPHA; BRAIN NATRIURETIC PEPTIDE; CREATININE; DENDROASPIS NATRIURETIC PEPTIDE; DOBUTAMINE; GLYCERYL TRINITRATE; KALIURETIC PEPTIDE; LONG ACTING NATRIURETIC PEPTIDE; MILRINONE; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE C; NESIRITIDE; PLACEBO; SALBUTAMOL; UNCLASSIFIED DRUG; URODILATIN; VASODILATOR AGENT;

ACUTE KIDNEY FAILURE; ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ASTHMA; BLOOD VESSEL TONE; CARDIOPULMONARY BYPASS; CHILD CARE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONGENITAL HEART DISEASE; CONGENITAL HEART MALFORMATION; CONGESTIVE HEART FAILURE; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC VALUE; DRUG EFFICACY; DRUG INFUSION; DRUG MECHANISM; FALLOT TETRALOGY; FLUID BALANCE; FONTAN PROCEDURE; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART SURGERY; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE SEPTUM DEFECT; HEMODYNAMICS; HORMONAL REGULATION; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HORMONE SYNTHESIS; HUMAN; INOTROPISM; INTENSIVE CARE; KIDNEY DISEASE; LUNG DISEASE; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; MORTALITY; NATRIURESIS; NONHUMAN; PEDIATRIC SURGERY; POPULATION RESEARCH; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RECEPTOR DOWN REGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VASCULAR RESISTANCE;

ADOLESCENT; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; CARDIOPULMONARY BYPASS; CHILD; CHILD, PRESCHOOL; CRITICAL CARE; HEART DEFECTS, CONGENITAL; HEART FAILURE, CONGESTIVE; HUMANS; INFANT; INFANT, NEWBORN; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN;

EID: 33745925892     PISSN: 15297535     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.PCC.0000224998.97784.A3     Document Type: Review

References (155)

1. de Bold AJ, Borenstein HB, Veress AT, et al: A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981; 28:89-94
2. Edwards BS, Zimmerman RS, Schwab TR, et al: Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res 1988; 62:191-195
3. Vesely DL: Natriuretic peptides and acute renal failure. Am J Physiol 2003; 285:F167-F177
4. Cody RJ, Atlas SA, Laragh JH, et al: Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest 1986; 78:1362-1374
5. Fujio N, Ohashi M, Nawata H, et al: Alpha-human atrial natriuretic polypeptide reduces the plasma arginine vasopressin concentration in human subjects. Clin Endocrinol 1986; 25:181-187
6. Cargill RI, Lipworth BJ: Pulmonary vasorelaxant activity of atrial natriuretic peptide and brain natriuretic peptide in humans. Thorax 1995; 50:183-185
7. Chu A, Morris KG, Kuehl WD, et al: Effects of atrial natriuretic peptide on the coronary arterial vasculature in humans. Circulation 1989; 80:1627-1635
8. Forssmann W, Meyer M, Forssmann K: The renal urodilatin system: Clinical implications. Cardiovasc Res 2001; 51:450-462
9. Mukoyama M, Nakao K, Hosoda K, et al: Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87:1402-1412
10. Holmes SJ, Espiner EA, Richards AM, et al: Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endo Metabol 1993; 76:91-96
11. Zellner C, Protter AA, Ko E, et al: Coronary vasodilator effects of BNP: Mechanisms of action in coronary conductance and resistance arteries. Am J Physiol 1999; 276:H1049-H1057
12. Schirger JA, Heublein DM, Chen HH, et al: Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure. Mayo Clin Proc 1999; 74:126-130
13. Lainchbury JG, Lisy O, Burnett JC Jr, et al: Actions of a novel synthetic natriuretic peptide on hemodynamics and ventricular function in the dog. Am J Physiol 2002; 282:R993-R998
14. Chen HH, Burnett JC: C-type natriuretic peptide: the endothelial component of the natriuretic peptide system. J Cardiovasc Pharmacol 1998; 32:S22-S28
15. Cargill RI, Struthers AD, Lipworth BJ: Human C-type natriuretic peptide: effects on the haemodynamic and endocrine responses to angiotensin II. Cardiovasc Res 1995; 29:108-111
16. Song DL, Kohse KP, Murad F: Brain natriuretic factor. Augmentation of cellular cyclic GMP, activation of particulate guanylate cyclase and receptor binding. FEBS Lett 1988; 232:125-129
17. Chinkers M, Garbers DL, Chang MS, et al: A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor. Nature 1989; 338:78-83
18. Munzel T, Feil R, Mulsch A, et al: Physiology and pathophysiology of vascular signaling controlled by guanosine 3′,5′-cyclic monophosphate-dependent protein kinase. Circulation 2003; 108:2172-2183
19. Dunn BR, Ichikawa I, Pfeffer JM, et al: Renal and systemic hemodynamic effects of synthetic atrial natriuretic peptide in the anesthetized rat. Circ Res 1986; 59:237-246
20. Saxenhofer H, Raselli A, Weidmann P, et al: Urodilatin, a natriuretic factor from kidneys, can modify renal and cardiovascular function in men. Am J Physiol 1990; 259:F832-F838
21. Costello-Boerrigter LC, Boerrigter G, Burnett JC Jr: Revisiting salt and water retention: New diuretics, aquaretics, and natriuretics. Med Clin North Am 2003; 87:475-491
22. Fuller F, Porter JG, Arfsten AE, et al: Atrial natriuretic peptide clearance receptor. Complete sequence and functional expression of cDNA clones. J Biol Chem 1988; 263:9395-9401
23. Kenny AJ, Stephenson SL: Role of endopeptidase-24.11 in the inactivation of atrial natriuretic peptide. FEBS Letters 1988; 232:1-8
24. Charles CJ, Espiner EA, Nicholls MG, et al: Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep. Am J Physiol 1996; 271:R373-R380
25. Yoshibayashi M, Kamiya T, Saito Y, et al: Plasma brain natriuretic peptide concentrations in healthy children from birth to adolescence: Marked and rapid increase after birth. Eur J Endocrinol 1995; 133:207-209
26. Mir TS, Marohn S, Laer S, et al: Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics 2002; 110:e76
27. Mir TS, Laux R, Hellwege HH, et al: Plasma concentrations of aminoterminal pro atrial natriuretic peptide and aminoterminal pro brain natriuretic peptide in healthy neonates: Marked and rapid increase after birth. Pediatrics 2003; 112:896-899
28. Levine TB, Francis GS, Goldsmith SR, et al: Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardial 1982; 49:1659-1666
29. Swedberg K, Eneroth P, Kjekshus J, et al: Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990; 82:1730-1736
30. Cody RT, Haas GJ, Binkley PF, et al: Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992; 85:504-509
31. Bolger AP, Sharma R, Li W, et al: Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation 2002; 106:92-99
32. Tsutamoto T, Kanamori T, Wada A, et al: Uncoupling of atrial natriuretic peptide extraction and cyclic guanosine monophosphate production in the pulmonary circulation in patients with severe heart failure. J Am Coll Cardiol 1992; 20:541-546
33. Maisel AS, Koon J, Krishnaswamy P, et al: Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001; 141:367-374
34. Tsutamoto T, Wada A, Maeda K, et al: Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. Eur Heart J 1999; 20:1799-1807
35. Cheng V, Kazanagra R, Garcia A, et al: A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: A pilot study. J Am Coll Cardiol 2001; 37:386-391
36. Maeda K, Tsutamoto T, Wada A, et al: High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000; 36:1587-1593
37. Januzzi JL Jr, Camargo CA, Anwaruddin S, et al: The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency department (PRIDE) study. Am J Cardiol 2005; 95:948-954
38. Bettencourt P, Azevedo A, Pimenta J, et al: N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004; 110:2168-2174
39. Davis M, Espiner E, Richards G, et al: Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 1994; 343:440-444
40. Cowie MR, Struthers AD, Wood DA, et al: Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350:1349-1353
41. Maisel AS, Krishnaswamy P, Nowak RM, et al: Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347:161-167
42. Mueller C, Scholer A, Laule-Kilian K, et al: Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004; 350:647-654
43. Kazanegra R, Cheng V, Garcia A, et al: A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: A pilot study. J Card Fail 2001; 7:21-29
44. Yamaguchi H, Yoshida J, Yamamoto K, et al: Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. J Am Coll Cardiol 2004; 43:55-60
45. de Lemos JA, Morrow DA, Bentley JH, et al: The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345:1014-1021
46. Qi W, Mathisen P, Kjekshus J, et al: Natriuretic peptides in patients with aortic stenosis. Am Heart J 2001; 142:725-732
47. Maron B, Tholakanahalli V, Zenovich A, et al: Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. Circulation 2004; 109:984-989
48. Hutfless R, Kazanegra R, Madani M, et al: Utility of B-type natriuretic peptide in predicting postoperative complications and outcomes in patients undergoing heart surgery. J Am Coll Cardiol 2004; 43:1873-1879
49. Rodeheffer RI: Measuring plasma B-type natriuretic peptide in heart failure: Good to go in 2004? J Am Coll Cardiol 2004; 44:740-749
50. Packer M: Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure? Circulation 2003; 108:2950-2953
51. Mitaka C, Hirata Y, Nagura T, et al: Increased plasma concentrations of brain natriuretic peptide in patients with acute lung injury. J Crit Care 1997; 12:66-71
52. Wu AH, Smith A, Wieczorek S, et al: Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 2003; 92:628-631
53. Koulouri S, Acherman RJ, Wong PC, et al: Utility of B-type natriuretic peptide in differentiating congestive heart failure from lung disease in pediatric patients with respiratory distress. Pediatr Cardiol 2004; 25:341-346
54. Cohen S, Springer C, Avital A, et al: Amino-terminal pro-brain-type natriuretic peptide: Heart or lung disease in pediatric respiratory distress? Pediatrics 2005; 115:1347-1350
55. Reynolds EW, Ellington JG, Vranicar M, et al: Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatrics 2004; 114:1297-1304
56. Kikuchi K, Nishioka K, Ueda T, et al: Relationship between plasma atrial natriuretic polypeptide concentration and hemodynamic measurements in children with congenital heart diseases. J Pediatr 1987; 111:335-342
57. Matsuoka S, Kurahashi Y, Miki Y, et al: Plasma atrial natriuretic peptide in patients with congenital heart diseases. Pediatrics 1988; 82:639-643
58. Suda K, Matsumura M, Matsumoto M: Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int 2003; 45:249-254
59. Tulevski II, Groenink M, van Der Wall EE, et al: Increased brain and atrial natriuretic peptides in patients with chronic right ventricular pressure overload: Correlation between plasma neurohormones and right ventricular dysfunction. Heart 2001; 86:27-30
60. Hjortdal VE, Stenbog EV, Ravn HB, et al: Neurohormonal activation late after cavopulmonary connection. Heart 2000; 83:439-443
61. Ohuchi H, Takasugi H, Ohashi H, et al: Stratification of pediatric heart failure on the basis of neurohormonal and cardiac autonomic nervous activities in patients with congenital heart disease. Circulation 2003; 108:2368-2376
62. Claudius I, Lan YT, Chang RK, et al: Usefulness of B-type natriuretic peptide as a noninvasive screening tool for cardiac allograft pathology in pediatric heart transplant recipients. Am J Cardiol 2003; 92:1368-1370
63. Wahlander H, Westerlind A, Lindstedt G, et al: Increased levels of brain and atrial natriuretic peptides after the first palliative operation, but not after a bidirectional Glenn anastomosis, in children with functionally univentricular hearts. Cardiol Young 2003; 13:268-274
64. Cowley CG, Bradley JD, Shaddy RE: B-type natriuretic peptide levels in congenital heart disease. Pediatr Cardiol 2004; 25:336-340
65. Mueller T, Gegenhuber A, Poelz W, et al: Biochemical diagnosis of impaired left ventricular ejection fraction - Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP). Clin Chem Lab Med 2004; 42:159-163
66. Mueller T, Gegenhuber A, Poelz W, et al: Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart 2005; 91:606-612
67. Tsutamoto T, Kanamori T, Morigami N, et al: Possibility of downregulation of atrial natriuretic peptide receptor coupled to guanylate cyclase in peripheral vascular beds of patients with chronic severe heart failure. Circulation 1993; 87:70-75
68. Seghaye MC, Duchateau J, Bruniaux J, et al: Endogenous nitric oxide production and atrial natriuretic peptide biological activity in infants undergoing cardiac operations. Crit Care Med 1997; 25:1063-1070
69. Costello JM, Backer CL, Checchia PA, et al: Alterations in the natriuretic hormone system related to cardiopulmonary bypass and modified ultrafiltration in patients with congenital heart disease. Pediatr Cardiol 2004; 25:347-353
70. Costello JM, Backer CL, Checchia PA, et al: Effect of cardiopulmonary bypass and surgical intervention on the natriuretic hormone system in children. J Thorac Cardiovasc Surg 2005; 130:822-829
71. Mizuno O, Onishi K, Dohi K, et al: Effects of therapeutic doses of human atrial natriuretic peptide on load and myocardial performance in patients with congestive heart failure. Am J Cardiol 2001; 88:863-866
72. Marcus LS, Hart D, Packer M, et al: Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 1996; 94:3184-3189
73. Mills RM, LeJemtel TH, Horton DP, et al: Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol 1999; 34:155-162
74. Yamamoto K, Burnett JC Jr, Redfield MM: Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart. Am J Physiol 1997; 273:H2406-H2414
75. Clarkson PB, Wheeldon NM, Macleod C, et al: Brain natriuretic peptide: Effect on left ventricular filling patterns in healthy subjects. Clin Sci 1995; 88:159-164
76. Clarkson PB, Wheeldon NM, MacFadyen RJ, et al: Effects of brain natriuretic peptide on exercise hemodynamics and neurohormones in isolated diastolic heart failure. Circulation 1996; 93:2037-2042
77. Saito Y, Nakao K, Nishimura K, et al: Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: Beneficial effects on left ventricular function. Circulation 1987; 76:115-124
78. Colucci WS, Elkayam U, Horton DP, et al: Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000; 343:246-253
79. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial. JAMA 2002; 287:1531-1540
80. Burger AJ, Elkayam U, Neibaur MT, et al: Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am J Cardiol 2001; 88:35-39
81. Burger AJ, Horton DP, LeJemtel T, et al: Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT study. Am Heart J 2002; 144:1102-1108
82. Silver MA, Horton DP, Ghali JK, et al: Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol 2002; 39:798-803
83. Abraham WT, Adams KF, Fonarow GC, et al: In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: An analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005; 46:57-64
84. Dec GW: Acute decompensated heart failure the shrinking role of inotropic therapy. J Am Coll Cardiol 2005; 46:65-67
85. Stevenson LW: Clinical use of inotropic therapy for heart failure: looking backward or forward? Part I: Inotropic infusions during hospitalization. Circulation 2003; 108:367-372
86. Sackner-Bernstein JD, Skopicki HA, Aaronson KD: Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005; 111:1487-1491
87. Elkayam U: Nesiritide may diminish the increased acute mortality risk associated with worsening renal function. Circulation 2005; 112:II-675
88. Wang DJ, Dowling TC, Meadows D, et al: Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 2004; 110:1620-1625
89. Elkayam U: Letter regarding article by Wang et al, "nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine." Circulation 2005; 111:e182-e183; author reply e182-e183
90. Topol EJ: Nesiritide - Not verified. N Engl J Med 2005; 353:113-116
91. Sackner-Bernstein J, Aaronson KD: Nesiritide - Not verified. N Engl J Med 2005; 353:1525-1527; author reply 1525-1527
92. Schreiner G: Nesiritide - Not verified. N Engl J Med 2005; 353:1525-1527; author reply 1525-1527
93. Sackner-Bernstein JD, Kowalski M, Fox M, et al: Short-term risk of death after treatment with nesiritide for decompensated heart failure - A pooled analysis of randomized controlled trials. JAMA 2005; 293:1900-1905
94. Abraham W: Nesiritide does not increase 30-day or 6-month mortality risk. Circulation 2005; 112:II-676
95. Scios. Panel of cardiology experts provides recommendations to Scios regarding Natrecor. Available at: http://www.sciosinc.com/scios/pr_1118721302. Accessed July 13, 2005
96. Scios. Scios announces the ETNA clinical trial with nesiritide. Available at: http://www.sciosinc.com/scios/pr_1127326387. Accessed October 21, 2005
97. Feingold B, Law YM: Nesiritide use in pediatric patients with congestive heart failure. J Heart Lung Transplant 2004; 23:1455-1459
98. Jefferies JL, Denfield SW, Dreyer WJ, et al: A prospective evaluation of nesiritide in pediatric heart failure. J Am Coll Cardiol 2005; 45:315A
99. Mahle WT, Cuadrado AR, Kirshborn PM, et al: Nesiritide in infants and children with congestive heart failure. Pediatr Crit Care Med 2005; 6:543-546
100. Suwa M, Seino Y, Nomachi Y, et al: Multi-center prospective investigation on efficacy and safety of carperitide for acute heart failure in the "real world" of therapy. Circulation Journal 2005; 69:283-290
101. Ationu A, Singer DR, Smith A, et al: Studies of cardiopulmonary bypass in children: Implications for the regulation of brain natriuretic peptide. Cardiovasc Res 1993; 27:1538-1541
102. Stewart JM, Gewitz MH, Clark BJ, et al: The role of vasopressin and atrial natriuretic factor in postoperative fluid retention after the Fontan procedure. J Thorac Cardiovasc Surg 1991; 102:821-829
103. Burch M, Lum L, Elliott M, et al: Influence of cardiopulmonary bypass on water balance hormones in children. Br Heart J 1992; 68:309-312
104. Kirshborn PM, Tsui SS, DiBernardo LR, et al: Blockade of endothelin-converting enzyme reduces pulmonary hypertension after cardiopulmonary bypass and circulatory arrest. Surgery 1995; 118:440-444
105. Lehot JJ, Villard J, Piriz H, et al: Hemodynamic and hormonal responses to hypothermic and normothermic cardiopulmonary bypass. J Cardiothorac Vasc Anes 1992; 6:132-139
106. Wernovsky G, Wypij D, Jonas RA, et al: Postoperative course and hemodynamic profile after the arterial switch operation in neonates and infants. A comparison of low-flow cardiopulmonary bypass and circulatory arrest. Circulation 1995; 92:2226-2235
107. Wessel DL, Adatia I, Giglia TM, et al: Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass. Circulation 1993; 88:2128-2138
108. Curello S, Ceconi C, De Giuli F, et al: Time course of human atrial natriuretic factor release during cardiopulmonary bypass in mitral valve and coronary artery diseased patients. Eur J Cardiothorac Surg 1991; 5:205-210
109. Hiramatsu T, Imai Y, Takanashi Y, et al: Hemodynamic effects of human atrial natriuretic peptide after modified Fontan procedure. Ann Thorac Surg 1998; 65:761-764
110. Yoshimura N, Yamaguchi M, Oshima Y, et al: Suppression of the secretion of atrial and brain natriuretic peptide after total cavopulmonary connection. J Thorac Cardiovasc Surg 2000; 120:764-769
111. Burch M, Shinebourne EA, Rigby ML, et al: Plasma atrial natriuretic peptide after the Fontan procedure and total cavopulmonary connexion. Int J Cardiol 1990; 27:161-165
112. Kharasch ED, Yeo KT, Kenny MA, et al: Influence of hypothermic cardiopulmonary bypass on atrial natriuretic factor levels. Can J Anaesth 1989; 36:545-553
113. Avidan MS, Meehan N, Ponte J, et al: Changes in brain natriuretic peptide concentrations following open cardiac surgery with cardioplegic cardiac arrest. Clin Chim Acta 2001; 303:127-132
114. Morimoto K, Mori T, Ishiguro S, et al: Perioperative changes in plasma brain natriuretic peptide concentrations in patients undergoing cardiac surgery. Surg Today 1998; 28:23-29
115. Hayashida N, Chihara S, Kashikie H, et al: Biological activity of endogenous atrial natriuretic peptide during cardiopulmonary bypass. Artif Organs 2000; 24:833-838
116. Supaporn T, Sandberg SM, Borgeson DD, et al: Blunted cGMP response to agonists and enhanced glomerular cyclic 3′,5′-nucleotide phosphodiesterase activities in experimental congestive heart failure. Kidney Int 1996; 50:1718-1725
117. Hamet P, Pang SC, Tremblay J: Atrial natriuretic factor-induced egression of cyclic guanosine 3′:5′-monophosphate in cultured vascular smooth muscle and endothelial cells. J Biol Chem 1989; 264:12364-12369
118. Koh GY, Nussenzveig DR, Okolicany J, et al: Dynamics of atrial natriuretic factor-guanylate cyclase receptors and receptor-ligand complexes in cultured glomerular mesangial and renomedullary interstitial cells. J Biol Chem 1992; 267:11987-11994
119. Roy LF, Ogilvie RI, Larochelle P, et al: Cardiac and vascular effects of atrial natriuretic factor and sodium nitroprusside in healthy men. Circulation 1989; 79:383-392
120. Sezai A, Shiono M, Orime Y, et al: Low-dose continuous infusion of human atrial natriuretic peptide during and after cardiac surgery. Ann Thorac Surg 2000; 69:732-738
121. Hayashi Y, Ohtani M, Hiraishi T, et al: Synthetic human alpha-atrial natriuretic peptide infusion in management after open heart operations. ASAIO J 2003; 49:320-324
122. Moazami N, Damiano RJ, Bailey MS, et al: Nesiritide (BNP) in the management of postoperative cardiac patients. Ann Thorac Surg 2003; 75:1974-1976
123. Samuels LE, Holmes EC, Lee L: Nesiritide as an adjunctive therapy in adult patients with heart failure undergoing high-risk cardiac surgery. J Thorac Cardiovasc Surg 2004; 128:627-629
124. Feldman DS, Ikonomidis JS, Uber WE, et al: Human B-natriuretic peptide improves hemodynamics and renal function in heart transplant patients immediately after surgery. J Card Fail 2004; 10:292-296
125. Salzberg SP, Filsoufi F, Anyanwu A, et al: High-risk mitral valve surgery: Perioperative hemodynamic optimization with nesiritide (BNP). Ann Thorac Surg 2005; 80:502-506
126. Simsic JMMD, Scheurer MMD, Tobias JDMD, et al: Perioperative hemodynamic effects of nesiritide following cardiac surgery in children. Pediatr Crit Care Med 2005; 6:399 (A)
127. Simsic JM, Reddy VS, Kanter KR, et al: Use of nesiritide (human B-type natriuretic peptide) in infants following cardiac surgery. Pediatr Cardiol 2004; 25:668-670
128. Sangawa K, Nakanishi K, Ishino K, et al: Atrial natriuretic peptide protects against ischemia-reperfusion injury in the isolated rat heart. Ann Thorac Surg 2004; 77:233-237
129. Kuga H, Ogawa K, Oida A, et al: Administration of atrial natriuretic peptide attenuates reperfusion phenomena and preserves left ventricular regional wall motion after direct coronary angioplasty for acute myocardial infarction. Circ J 2003; 67:443-448
130. D'Souza SP, Yellon DM, Martin C, et al: B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am J Physiol 2003; 284:H1592-H1600
131. Wakui S: Experimental study on myocardial protection by adjunct use of carperitide (hANP) in cardiac surgery. Ann Thorac Cardiovasc Surg 2005; 11:12-20
132. Abdallah Y, Gkatzoflia A, Pieper H, et al: Mechanism of cGMP-mediated protection in a cellular model of myocardial reperfusion injury. Cardiovasc Res 2005; 66:123-131
133. Mitaka C, Hirata Y, Habuka K, et al: Atrial natriuretic peptide improves pulmonary gas exchange by reducing extravascular lung water in canine model with oleic acid-induced pulmonary edema. Crit Care Med 2002; 30:1570-1575
134. Mitaka C, Hirata Y, Nagura T, et al: Beneficial effect of atrial natriuretic peptide on pulmonary gas exchange in patients with acute lung injury. Chest 1998; 114:223-228
135. Igaki T, Itoh H, Suga S, et al: C-type natriuretic peptide in chronic renal failure and its action in humans. Kidney Int 1996; 55:S144-S147
136. Cataliotti A, Malatino LS, Jougasaki M, et al: Circulating natriuretic peptide concentrations in patients with end-stage renal disease: Role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc 2001; 76:1111-1119
137. Rahman SN, Kim GE, Mathew AS, et al: Effects of atrial natriuretic peptide in clinical acute renal failure. Kidney Int 1994; 45:1731-1738
138. Allgren RL, Marbury TC, Rahman SN, et al: Anaritide in acute tubular necrosis. N Engl J Med 1997; 336:828-834
139. Lewis J, Salem MM, Chertow GM, et al: Atrial natriuretic factor in oliguric acute renal failure. Anaritide Acute Renal Failure Study Group. Am J Kidney Dis 2000; 36:767-774
140. Meyer M, Pfarr E, Schirmer G, et al: Therapeutic use of the natriuretic peptide ularitide in acute renal failure. Ren Fail 1999; 21:85-100
141. Kurnik BR, Allgren RL, Genter FC, et al: Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 1998; 31:674-680
142. Shaw SG, Weidmann P, Hodler J, et al: Atrial natriuretic peptide protects against acute ischemic renal failure in the rat. J Clin Invest 1987; 80:1232-1237
143. Mitaka C, Hirata Y, Habuka K, et al: Atrial natriuretic peptide infusion improves ischemic renal failure after suprarenal abdominal aortic cross-clamping in dogs. Crit Care Med 2003; 31:2205-2210
144. Valsson F, Ricksten SE, Hedner T, et al: Effects of atrial natriuretic peptide on acute renal impairment in patients with heart failure after cardiac surgery. Intensive Care Med 1996; 22:230-236
145. Sward K, Valson F, Ricksten S-E: Long-term infusion of atrial natriuretic peptide (ANP) improves renal blood flow and glomerular filtration rate in clinical acute renal failure. Acta Anaesthesiol Scand 2001; 45:536-542
146. Mitaka C, Hirata Y, Nagura T, et al: Plasma alpha-human atrial natriuretic peptide concentration in patients with acute lung injury. Am Rev Respir Dis 1992; 146:43-46
147. Tanabe M, Ueda M, Endo M, et al: Effect of acute lung injury and coexisting disorders on plasma concentrations of atrial natriuretic peptide. Crit Care Med 1994; 22:1762-1768
148. Tanabe M, Ueda M, Endo M, et al: The effect of atrial natriuretic peptide on pulmonary acid injury in a pig model. Am J Respir Crit Care Med 1996; 154:1351-1356
149. Fluge T, Forssmann WG, Kunkel G, et al: Bronchodilation using combined urodilatin-albuterol administration in asthma: A randomized, double-blind, placebo-controlled trial. Eur J Med Res 1999; 4:411-415
150. Wiedemann R, Ghofrani HA, Weissmann N, et al: Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension: Response to iloprost inhalation. J Am Coll Cardiol 2001; 38:1130-1136
151. Ishii J, Nomura M, Ito M, et al: Plasma concentration of brain natriuretic peptide as a biochemical marker for the evaluation of right ventricular overload and mortality in chronic respiratory disease. Clin Chim Acta 2000; 301:19-30
152. Nagaya N, Nishikimi T, Uematsu M, et al: Secretion patterns of brain natriuretic peptide and atrial natriuretic peptide in patients with or without pulmonary hypertension complicating atrial septal defect. Am Heart J 1998; 136:297-301
153. Nagaya N, Nishikimi T, Uematsu M, et al: Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102:865-870
154. Kojima T, Fukuda Y, Hirata Y, et al: Changes in vasopressin, atrial natriuretic factor, and water homeostasis in the early stage of bronchopulmonary dysplasia. Pediatr Res 1990; 27:260-263
155. Ivy DD, Kinsella JP, Wolfe RR, et al: Atrial natriuretic peptide and nitric oxide in children with pulmonary hypertension after surgical repair of congenital heart disease. Am J Cardiol 1996; 77:102-105